Aclaris Therapeutics (ACRS) Misses Q4 EPS by 1c

Aclaris Therapeutics (NASDAQ: ACRS) reported Q4 EPS of ($0.16), $0.01 worse than the analyst estimate of ($0.15). Revenue for the quarter came in at $1.3 million versus the consensus estimate of $1.94 million.

For earnings history and earnings-related data on Aclaris Therapeutics (ACRS) click here.

You May Also Be Interested In

• Lennar Corp. (LEN) Mentioned Cautiously at Hunterbook
• Ishares Msci France Etf (EWQ) call put ratio 1 call to 1 put a share price up 1.5%
• Aclaris Therapeutis (ACRS) Reiterated at Overweight by Cantor Fitzgerald Post Tilrekimig Ph2 Data